C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10815048-!A.str

chain nodes:

14 15 16 17 18 19 23 24 25 27

ring nodes:

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds:

2-12 5-27 11-14 14-15 15-16 15-17 23-24 23-25

ring bonds:

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds:

1-2 1-6 2-3 2-12 3-4 4-5 5-6 5-27 11-14 14-15 15-16 15-17 23-24 23-25

normalized bonds:

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems:

containing 1: 7:

G2:[*1],[*2]

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 14:CLAS\$15:CLAS\$16:CLAS\$17:CLAS\$18:Atom 19:CLAS\$23:CLAS\$24:CLAS\$25:Atom 26:Atom 27:CLAS\$

C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10815048-Z.str

chain nodes:

14 15 16 17 18 19 23 24 25 27 28

ring nodes:

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds:

2-12 5-27 11-14 14-15 15-16 15-17 23-24 23-25 27-28

ring bonds:

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds:

1-2 1-6 2-3 2-12 3-4 4-5 5-6 5-27 11-14 14-15 15-16 15-17 23-24 23-25 27-28

normalized bonds:

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems:

containing 1: 7:

G2:[*1],[*2]

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 14:CLAS\$15:CLAS\$16:CLAS\$17:CLAS\$18:Atom 19:CLAS\$23:CLAS\$24:CLAS\$25:Atom 26:Atom 27:CLAS\$28:CLAS\$

Welcome to STN International! Enter x:x

LOGINID:sssptau122ebb

PASSWORD:

* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * SESSION RESUMED IN FILE 'REGISTRY' AT 19:11:14 ON 19 FEB 2007 FILE 'REGISTRY' ENTERED AT 19:11:14 ON 19 FEB 2007 COPYRIGHT (C) 2007 American Chemical Society (ACS) COST IN U.S. DOLLARS SINCE FILE

SESSION ENTRY 7.65 8.07

TOTAL

FULL ESTIMATED COST

=> file reg COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY 7.65 8.07 FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 19:11:25 ON 19 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

18 FEB 2007 HIGHEST RN 921759-52-6 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: 18 FEB 2007 HIGHEST RN 921759-52-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d his

(FILE 'HOME' ENTERED AT 19:04:44 ON 19 FEB 2007)

FILE 'REGISTRY' ENTERED AT 19:06:00 ON 19 FEB 2007 STRUCTURE UPLOADED

L1L2 34 S L1

FILE 'REGISTRY' ENTERED AT 19:11:25 ON 19 FEB 2007

=> s 11SAMPLE SEARCH INITIATED 19:12:11 FILE 'REGISTRY' 10815048

SAMPLE SCREEN SEARCH COMPLETED - 622 TO ITERATE

100.0% PROCESSED

622 ITERATIONS

34 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:

ONLINE **COMPLETE** **COMPLETE**

BATCH

10944 TO 13936

PROJECTED ITERATIONS: PROJECTED ANSWERS:

331 TO

34 SEA SSS SAM L1

=> s ll sss full

FULL SEARCH INITIATED 19:12:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 12504 TO ITERATE

100.0% PROCESSED

12504 ITERATIONS

661 ANSWERS


SEARCH TIME: 00.00.02


L4

661 SEA SSS FUL L1

=>

Uploading C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10815048-Z.str





10815048

chain nodes :

14 15 16 17 18 19 23 24 25 27 28

ring nodes :

chain bonds :

2-12 5-27 11-14 14-15 15-16 15-17 23-24 23-25 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

1-2 1-6 2-3 2-12 3-4 4-5 5-6 5-27 11-14 14-15 15-16 15-17 23-24 23-25

27-28

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems:

containing 1: 7:

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:CLASS 28:CLASS

L5 STRUCTURE UPLOADED

STR

=> d 15

L5 HAS NO ANSWERS

L5

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sub=14 full

FULL SUBSET SEARCH INITIATED 19:13:33 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 660 TO ITERATE

100.0% PROCESSED 660 ITERATIONS 655 ANSWERS

SEARCH TIME: 00.00.01

L6 655 SEA SUB=L4 SSS FUL L5

=> s 14 not 16

L7 6 L4 NOT L6

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 214.55 222.62

FILE 'CAPLUS' ENTERED AT 19:14:14 ON 19 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2007 VOL 146 ISS 9 FILE LAST UPDATED: 18 Feb 2007 (20070218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s 17
L8 3 L7
```

=> d 18 1-3 bib abs hitstr

```
L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
```

AN 2004:857558 CAPLUS

DN 141:350197

TI Preparation of phospholipase c inhibitors for use in treating inflammatory disorders

IN Lagu, Bharat; Rupert, Kenneth; Wachter, Michael

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent LA English

FAN. CNT 1

FAN.CNT 1 PATENT NO.				KIN	0	DATE	•	i	APPL	CAT:	гои 1	10.		D.	ATE				
PI	WO 2004087654			A2 20041014 A3 20050127			WO 2004-US9839					20040331							
	WO	Z004			ħΤ			AU,		ВΣ	BB	B.G.	RR	ВW	RY.	BZ.	CA.	CH.	
		VV :						DE,											
								ID,											
								LV,											
								PL,											
								ΤŻ,											
		RW:						MW,											
			BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	
	•	•	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	
			SK.	TR.	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	
			TD.	•	•	•	•												
	US	2004				A1		2004	1125		US 2	004-	8150	48		2	0040	331	
PRAT		2003				P		2003	0331										
os		RPAT				_													
GI	. 11. 1		- · · ·	J J J I															
GI																			

$$L^2$$
 NH
 Y
 $N-R^5$
 $CH_2)_n$
 I

AB This invention is directed to preparation of heterocyclyl-substituted anilino phospholipase C inhibitor compds. I [L1 = (un)substituted-alkyl, -heterocyclic carbonyl, -alkylsulfonyl, etc.; L2 = (un)substituted-alkyl, -alkylsulfonyl, -N-alkylamide, etc.; R5 = (un)substituted-alkyl, -cycloalkyl, -aryl; Y = one or more optionally present (un)substituted alkyl substituents; n = 1-2] useful in treating or ameliorating an inflammatory disorders and/or restenosis and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Thus, e.g., II was prepared in six steps employing a solid phase synthesis starting from piperazine (47% yield). Solution phase methods for preparing I are also presented. I possessed IC50 values ranging from 8.7 to >25 μM. The present invention is further directed to pharmaceutical compns. comprising the compds. of the present invention and to methods for treating conditions affected by phospholipase modulation.

TT 774582-81-9P 774582-82-0P 774582-83-1P

774582-84-2P 774582-92-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; solid phase synthesis of piperazinyl derivs. and analogs thereof as phospholipase C inhibitors for treatment of inflammatory disorders)

RN 774582-81-9 CAPLUS

CN Benzamide, N-[2-[4-(diphenylmethyl)-1-piperazinyl]-5-(1-piperazinylcarbonyl)phenyl]-4-methyl- (9CI) (CA INDEX NAME)

NAME)

RN 774582-82-0 CAPLUS
CN 3-Furancarboxamide, 5-(4-chlorophenyl)-N-[2-[4-(diphenylmethyl)-1-piperazinyl]-5-(1-piperazinylcarbonyl)phenyl]-2-methyl- (9CI) (CA INDEX

O Me

C O

NH

NH

CHPh2

RN 774582-83-1 CAPLUS
CN 2-Furancarboxamide, N-[2-[4-(diphenylmethyl)-1-piperazinyl]-5-(1-piperazinylcarbonyl)phenyl]- (9CI). (CA INDEX NAME)

774582-84-2 CAPLUS RNPropanamide, N-[2-[4-(diphenylmethyl)-1-piperazinyl]-5-(1-CN piperazinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)

774582-92-2 CAPLUS RNCN

2-Furancarboxamide, N-[2-[4-(diphenylmethyl)-1-piperazinyl]-5-(1-piperazinylcarbonyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

774582-83-1 CRN C33 H35 N5 O3 CMF

2 CM

76-05-1 CRN C2 H F3 O2 CMF

ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN rs

2002:638288 CAPLUS AN

137:185513 DN

Preparation of piperidine and piperazine derivatives as inhibitors of TI $p38\alpha$ kinase

Goehring, R. richard; Mavunkel, Babu J.; Liu, David Y.; Schreiner, George IN F.; Leudtke, Gregory; Lewicki, John A.

PA

U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S. Ser. No. 385,494. SO CODEN: USXXCO

DT. Patent

English LΆ

FAN.	CNT 3 PATENT NO.	KIND	DATE	APPLICATION NO.	DATE 		
PI	us 2002115671 us 6541477	A1 B2	20020822	us 2001-796997	20010228		
	US 6410540	B1	20020625	US 1999-385494	19990827		
PRAI	US 1999-385494 US 2000-185571P	A2 P	20000228				
	US 1998-98219P	P	19980828				

US 1999-125343P P 19990319 OS MARPAT 137:185513 GI

Ar1-x1-N $z-x^2-Ph$

AB The title compds. I [Arl = furanyl optionally substituted; Xl = CO; Z = N, CH; X2 = CH2, isostere; Ph may be optionally substituted], inhibitors of p38 α kinase, were prepared For example, 1-benzoyl-4-benzylpiperidine was prepared in 96% yield by reaction of 4-benzylpiperidine and PhCOCl in the presence of disopropylethylamine in CH2Cl2. In p38 α kinase inhibition assays, I showed substantial inhibition at 15 μ M, some as high as 99%. I are useful for the treatment of conditions associated with activation of p38 α , in particular inflammation and cardiac conditions (no data).

(preparation of piperidine and piperazine derivs. as inhibitors of p38 α kinase for treatment of inflammation and cardiac conditions)

RN 358985-88-3 CAPLUS

CN Acetamide, N-[2-(4-methyl-1-piperazinyl)-5-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:661422 CAPLUS

DN 135:227015

TI Preparation of piperidine and piperazine derivatives as inhibitors of $p38-\alpha$ kinase

IN Goehring, Richard R.; Mavunkel, Babu J.; Liu, David Y.; Schreiner, George F.; Luedtke, Gregory; Lewicki, John A.

PA Scios, Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

EVN CNIL 3

FAN.	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
ΡI	WO 2001064676	A2	20010907	WO 2001-US6715	20010228		
	WO 2001064676	A3	20020328				
	M. AF AG A	T. AM AT	r. Aii. A7. I	BA. BB. BG. BR. BY. BZ.	. CA. CH. CN.		

GΙ

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-185571P P 20000228

OS MARPAT 135:227015

$$Ar^{1}X^{1}-N \qquad z-X^{2}Ar^{2}$$

The title compds. I [Ar1 = furanyl optionally substituted; X1 = CO; Z = N, CH; X2 = CH2, isostere; Ar2 = substituted Ph], inhibitors of p38- α kinase, were prepared E.g., 1-benzoyl-4-benzylpiperidine was prepared by reaction of 4-benzylpiperidine and PhCOCl.

IT 358985-88-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine and piperazine derivs. as inhibitors of $p38-\alpha$ kinase)

RN 358985-88-3 CAPLUS

CN Acetamide, N-[2-(4-methyl-1-piperazinyl)-5-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

=> file caold SINCE FILE TOTAL COST IN U.S. DOLLARS **ENTRY** SESSION 18.63 241.25 FULL ESTIMATED COST SINCE FILE TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SESSION ENTRY -2.34-2.34CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 19:17:47 ON 19 FEB 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 17 L9 0 L7

=> log h SINCE FILE TOTAL COST IN U.S. DOLLARS ENTRY SESSION 0.45 241.70 FULL ESTIMATED COST SINCE FILE TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) ENTRY SESSION 0.00 -2.34CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES STN INTERNATIONAL SESSION SUSPENDED AT 19:18:04 ON 19 FEB 2007